Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

ClinicalTrials.gov ID: NCT02982915

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02982915. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.

Study identification

NCT ID: NCT02982915
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Longeveron Inc.; Industry
Enrollment: 62 participants

Conditions and interventions

Conditions

Aging Frailty

Interventions

Longeveron Mesenchymal Stem Cells (LMSCs) Biological
Fluzone High Dose Vaccine Biological

Biological

Eligibility (public fields only)

Age range: 65 Years to 90 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2016 (Actual)
Primary completion: Sep 2021 (Actual)
Completion: Sep 2022 (Actual)
Last update posted: Nov 4, 2022

2016 – 2022

United States locations

U.S. sites: 6
U.S. states: 2
U.S. cities: 5

Facility	City	State	ZIP	Site status
Clinical Research of South Florida	Coral Gables	Florida	33134	—
Clinical Physiology Associates	Fort Myers	Florida	33912	—
University of Miami	Miami	Florida	33136	—
Vista Health Research	Miami	Florida	33176	—
Johns Hopkins University	Baltimore	Maryland	21224	—
Optimal Research LLC	Rockville	Maryland	20850	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02982915, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 4, 2022 · Synced Nov 15, 2026